ALK and non-small cell lung carcinoma: Results from the phase 3 ASCEND-4 study demonstrated consistent, high, and durable antitumor efficacy of ceritinib in patients with advanced ALK-rearranged NSCLC.[5] On the molecular findings, the patient underwent ceritinib therapy (450mg orally once daily), which ameliorated her clinical symptoms significantly and promptly.